ClinicalTrials.gg
CompletedNCT07884461Updated Oct 20, 2026

The First-in-Human Study of GW906 Injection

A Phase 1 interventional study of GW906 injection and Placebo in Hypertension, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Mar 2025, registered Sep 2026).
Updated Oct 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 408 studies in Hypertension with a site in China — 123 open to participants now, 146 under way, 12 of them phase 3. Hypertension · China.

Enrollment
261st of 306
40 · median 255
Started
2025
with 46 others
Phase 1
19 of 408
4 open now
Registered
398th of 408
by date
Lead sponsor
9 of 408
Shenzhen Salubris Pharmaceuticals Co., Ltd.

Among the 408 studies in Hypertension with a site in China, this one is the 261st largest by enrollment of the 306 interventional ones that give a count, is one of 47 that started in 2025, is one of 19 in phase 1, and was the 398th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

123 of the 408 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:

118 more — sign in →

All 123 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 408 studies in Hypertension with a site in China, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, placebo-controlled, single-dose, dose-escalation trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GW906 in healthy subjects and subjects with mild hypertension, as well as to conduct an initial exploration of its clinical efficacy.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • GW906
  • single-dose-escalation
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-60 years (inclusive) at the time of signing the form, gender is not restricted.
  • 19.0-30.0 kg/m² (inclusive) and weight ≥50 kg during the screening period.
  • No use of antihypertensive medications, including ACEIs, ARBs, CCBs, ARNIs, diuretics, etc., within 30 days prior to signing the informed consent form.
  • Mean seated SBP measured by AOBP during the screening and baseline periods was 110-159 mmHg (inclusive) and DBP was 70-99 mmHg (inclusive).
  • 12-lead (ECG) results are normal or, according to the investigator, abnormalities are clinically insignificant, and was \<450 ms for males and \<470 ms for females.
  • Before any procedure related to the study begins, the applicant voluntarily signs a written informed consent form, fully understands the purpose and significance of the study, and is willing to comply with the study protocol

Exclusion criteria

Exclusion Criteria:

  • Secondary hypertension.
  • Orthostatic hypotension (defined as a decrease in SBP ≥20 mmHg or DBP ≥10 mmHg within 1 minute after standing from a supine position).
  • History of syncope.
  • Metabolic and cardiovascular diseases: ① Diabetes mellitus, or laboratory tests showing fasting blood glucose ≥7.0 mmol/L (126 mg/dL) or (HbA1c) ≥6.5%; ② History of cardiovascular events (e.g., stroke, , myocardial infarction, unstable angina, coronary artery bypass grafting, percutaneous coronary intervention, hospitalization for heart failure) or valvular heart disease; ③ Other conditions deemed by the investigators to potentially affect the trial or increase the risk to the participants.
  • Liver or kidney dysfunction, psychiatric disorders, neurological disorders, tumors, hematological disorders, or other uncontrolled/serious conditions, which the investigator deems may affect trial conduct or increase participant risk.
  • Clinically relevant medical history or comorbidities, which the investigator deems may affect trial compliance or data interpretation.
  • History of allergy to ≥2 drugs, or known allergy to oligonucleotides or N-acetylgalactosamine (GalNAc).
  • History of subcutaneous injection intolerance, or significant abdominal scarring (e.g., due to surgery or burns), which may affect administration of the study drug or assessment of local tolerance.
  • Underwent major surgery within 6 months prior to screening, or plans to undergo surgery during the study.
  • Lost more than 10% of body weight within 6 months prior to screening, or plans to lose weight during the study.
  • History of hospitalization or any clinically significant illness within 3 months prior to randomization, which the investigator deems may affect trial conduct or data interpretation.
  • Physical examination and vital signs (excluding blood pressure) results during the screening period are deemed abnormal and clinically significant by the investigator.
  • Laboratory test results during the screening period are deemed abnormal and clinically significant by the investigator, including but not limited to:

    1. Creatinine level exceeding the (ULN), or \<90 mL/min/1.73 m².
    2. (ALT), aspartate aminotransferase (AST), direct , and total bilirubin ≥1.5 times the ULN, deemed abnormal and clinically significant by the investigator.
    3. Serum potassium >5 mmol/L.
  • Positive results for surface antigen, virus antibody, antibody, or Treponema pallidum antibody screening during the screening period.
  • Vaccinated within 8 weeks prior to screening, or planned to be vaccinated during the study.
  • Individuals who have received the drug or participated in or are currently participating in other clinical trials within 30 days or 5 half-lives (whichever is longer) prior to randomization.
  • Individuals who have used, are currently using, or are expected to use, any herbal remedies, supplements, over-the-counter or prescription drugs that affect blood pressure, or other drugs or treatments that the investigator determines may affect the participant's blood pressure or the conduct of the trial within 30 days or 5 half-lives (whichever is longer) prior to administration.
  • Women who are pregnant, breastfeeding, or plan to become pregnant during the study period and within one year after administration; women with a positive pregnancy test result at the screening or baseline period; or women of childbearing age who have had unprotected sex with their partner within 14 days prior to or during the screening period.
  • The participants or their partners is unwilling to comply with requirements (such as complete abstinence, condoms, IUDs, tubal ligation, or other non-pharmacological contraceptive methods) during the study period and within one year after administration.
  • Plans to donate sperm or eggs during the study and for 1 year after dosing.
  • Alcohol intake ≥14 units per week within 30 days prior to administration of the investigational drug (1 unit = 10g alcohol ≈ 360mL beer/150mL wine/ 45 mL of 40% alcohol-by-volume spirits); or unwillingness to comply with the alcohol restriction requirements during the study period (alcohol intake \<14 units/week, abstinence from alcohol within 24 hours prior to each visit); or a positive breathalyzer test (if a positive breathalyzer test is due to social drinking, a retest may be conducted before D-2 at the investigator's discretion, and the retest result shall prevail).
  • Smoking ≥5 cigarettes per day within 3 months prior to screening, or planning to smoke ≥5 cigarettes per day during the study period.
  • Positive drug abuse screening (if a false positive is due to methodological reasons, or a positive result is due to drugs (such as influenza or cold medicine), a retest may be conducted before D-2 at the investigator's discretion, and the retest result shall prevail).
  • Excessive daily consumption of tea, coffee, and/or caffeinated beverages (≥8 cups/day, 1 cup = 250 mL) within the 3 months prior to randomization, or intake of caffeinated (e.g., coffee, strong tea, cola, chocolate, etc.) or rich in xanthines (animal organs, sardines, soy products, etc.) foods or beverages within 48 hours prior to randomization.
  • Receiving a blood transfusion within the 3 months prior to screening, or a total blood donation/loss ≥400 mL; or a total blood donation/loss ≥200 mL within 1 month prior to screening.
  • Unwilling or unable to avoid strenuous exercise within 48 hours prior to each blood sample collection.
  • Other circumstances deemed unsuitable for participation by the investigator (e.g., circumstances that may cause blood pressure fluctuations or affect the diurnal rhythm of blood pressure)
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    GW906 Group

    Drug: GW906 injection

  • Placebo comparator
    Placebo Group

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse events (AE) and serious adverse events (SAE)

    Time frame: Day 0 to Month 3

Secondary outcomes

  1. The change in serum angiotensinogen (AGT) levels compared to the baseline after administration

    Time frame: To Month 3

07

Study locations

1 site
  • Peking University Third Hospital
    Beijing, Beijing Municipality 100191, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Aug 2026, 16 months.

Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 16 months is above that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2026
First posted
Oct 20, 2026
StartActual
Mar 29, 2025
Primary completionActual
Aug 24, 2026
CompletionActual
Aug 24, 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07884461
Responsible party
Sponsor
First posted
Oct 20, 2026
Start date
Mar 29, 2025
Primary completion
Aug 24, 2026
Completion
Aug 24, 2026
Last update
Oct 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GW906

Start the discussion